New hope for kids with MS: ocrelizumab trial launches

NCT ID NCT04075266

First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 28 times

Summary

This study tests the safety and dosing of ocrelizumab in 23 children and teens (ages 10–18) with relapsing-remitting multiple sclerosis over 2 years. The goal is to find the right dose for a future larger study. Participants must have a diagnosis of RRMS and stable symptoms before starting.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • AOU Policlinico V. Emanuele - P.O G. Rodolico

    Catania, Sicily, 95123, Italy

  • Azienda Ospedaliera Sant'Andrea

    Rome, Lazio, 00189, Italy

  • Boston Childrens Hospital

    Boston, Massachusetts, 02115, United States

  • Childrens National Health Center

    Washington D.C., District of Columbia, 20010, United States

  • Cleveland Clinic

    Cleveland, Ohio, 44195, United States

  • Dzieci?cy Szpital Kliniczny im. Józefa Polikarpa Brudzi?skiego

    Warsaw, 02-091, Poland

  • Instytut Pomnik Centrum Zdrowia Dziecka

    Warsaw, 04-730, Poland

  • Ospedale Pediatrico Bambino Gesù

    Rome, Lazio, 00165, Italy

  • University of Colorado Denver Childrens Hospital Rocky Mountain MS Center

    Aurora, Colorado, 80045, United States

  • Uniwersytecki Szpital Kliniczny w Poznaniu

    Późna, 60-355, Poland

  • Uniwersyteckie Centrum Kliniczne

    Gda?sk, 80-952, Poland

  • Washington Universtiy school of Medicine

    St Louis, Missouri, 63110, United States

Conditions

Explore the condition pages connected to this study.